Virginia Commonwealth University

VCU Massey Cancer Center

Clinical news

Massey becomes the only medical provider in Richmond to offer Interleukin-2 therapy

VCU Massey Cancer Center is now offering FDA-approved Interleukin-2 (IL-2) therapy for metastatic melanoma and metastatic renal cell carcinoma, making Massey the only medical provider in the Richmond area to offer this service. IL-2 treatment is a type of immunotherapy that stimulates the body’s immune system to recognize and kill tumor cells.

Continue reading →

National clinical trials offered at Massey utilize precision medicine aimed at improving treatment of early-stage lung cancer

VCU Massey Cancer Center is currently offering clinical trials for patients with early-stage lung cancer that utilize cutting-edge precision medicine techniques with the aim of improving treatment. This group of three integrated national clinical trials known as ALCHEMIST – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials – use next-generation sequencing to identify patients with early-stage lung cancer whose tumors harbor specific and uncommon changes in two particular genes, epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK), thought to drive cancer growth. 

Continue reading →

Massey research leads to multi-institutional phase 1 clinical trial for relapsed/refractory aggressive lymphomas

Steven Grant, M.D., in the lab.

Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., is the co-principal investigator (PI) on a National Comprehensive Cancer Network (NCCN) grant funding a phase 1 clinical trial testing the drugs volasertib and belinostat in patients with relapsed and refractory aggressive B-cell and T-cell lymphomas. The $453,852 award will help implement the clinical trial at Massey, Yale Comprehensive Cancer Center and Johns Hopkins’ Sidney Kimmel Comprehensive Cancer Center. 

Continue reading →

International study co-led by Massey researcher finds ovarian suppression reduces breast cancer recurrence for some young women

Results from a large international study co-led by a VCU Massey Cancer Center physician-scientist concluded that adding ovarian suppression to adjuvant therapy (post surgery) with tamoxifen substantially reduced breast cancer recurrence in young, premenopausal women with hormone-sensitive early breast cancer who received chemotherapy because of a high risk for recurrence of their cancer.

Continue reading →

Innovative national clinical trial offered at Massey utilizes precision medicine techniques to improve lung cancer treatment

VCU Massey Cancer Center is conducting a novel clinical trial in collaboration with the National Cancer Institute and cancer centers nationwide for patients with squamous cell lung cancer, a type of non-small cell lung cancer with different genetic changes driving the growth of cancerous cells. These genetic changes vary from person to person, and this clinical trial, named Lung-MAP, is unique in offering a targeted approach to better treat the patient.

Continue reading →